Krystal Biotech, Inc.

How big is Krystal Biotech, Inc.?

As of Jun 18, Krystal Biotech, Inc. has a market capitalization of $3.76 billion, with net sales of $333.44 million and a net profit of $123.96 million over the latest four quarters.

Market Cap: As of Jun 18, Krystal Biotech, Inc. has a market capitalization of 3,757.41 million, classifying it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Krystal Biotech, Inc. reported net sales of 333.44 million and a net profit of 123.96 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 946.38 million and total assets of 1,055.84 million.

What does Krystal Biotech, Inc. do?

Krystal Biotech, Inc. is a gene therapy company focused on developing treatments for dermatological diseases, with a market cap of approximately $3.76 billion. As of March 2025, it reported net sales of $88 million and a net profit of $36 million.

Overview: <BR>Krystal Biotech, Inc. is a gene therapy company engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a small-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 88 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 36 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 3,757.41 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 27.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.63 <BR>Return on Equity: 14.98% <BR>Price to Book: 3.82<BR><BR>Contact Details: <BR>Address: 2100 Wharton St Ste 701, PITTSBURGH PA: 15203-1973 <BR>Tel: 1 412 5865830 <BR>Website: https://www.krystalbio.com/

Should I buy, sell or hold Krystal Biotech, Inc.?

Who are in the management team of Krystal Biotech, Inc.?

As of March 2022, the management team of Krystal Biotech, Inc. includes Chairman and CEO Mr. Krish Krishnan, COO Mrs. Suma Krishnan, Lead Independent Director Mr. R. Douglas Norby, and Directors Dr. Jing Marantz, Dr. Christopher Mason, Mr. Julian Gangolli, and Mr. Kirti Ganorkar. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Krystal Biotech, Inc. includes:<BR><BR>- Mr. Krish Krishnan, who serves as the Chairman of the Board, President, and Chief Executive Officer.<BR>- Mrs. Suma Krishnan, the Founder, Chief Operating Officer, and Director.<BR>- Mr. R. Douglas Norby, who is the Lead Independent Director.<BR>- Dr. Jing Marantz, serving as a Director.<BR>- Dr. Christopher Mason, also a Director.<BR>- Mr. Julian Gangolli, who is an Independent Director.<BR>- Mr. Kirti Ganorkar, another Independent Director. <BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Is Krystal Biotech, Inc. technically bullish or bearish?

As of September 26, 2025, Krystal Biotech, Inc. shows a mildly bullish technical trend, with mixed signals across time frames, outperforming the S&P 500 in the short term but underperforming over the past year.

As of 26 September 2025, the technical trend for Krystal Biotech, Inc. has changed from sideways to mildly bullish. The weekly MACD is mildly bullish, while the monthly MACD is mildly bearish, indicating mixed signals across time frames. The RSI shows a bullish stance on the monthly chart but no signal on the weekly. Bollinger Bands are bullish weekly but sideways monthly, and the KST is bullish weekly while mildly bearish monthly. The Dow Theory indicates a mildly bullish trend on the monthly basis with no trend weekly. The On-Balance Volume is mildly bullish for both weekly and monthly periods.<BR><BR>In terms of performance, Krystal Biotech has outperformed the S&P 500 over the past week and month, with returns of 2.60% and 14.26% respectively, compared to -0.31% and 2.75% for the index. However, it has underperformed over the past year with a return of -5.94% against the S&P 500's 15.64%. Overall, the current technical stance is mildly bullish, driven by the weekly MACD, KST, and OBV indicators.

Is Krystal Biotech, Inc. overvalued or undervalued?

As of November 7, 2025, Krystal Biotech, Inc. is fairly valued with a P/E ratio of 27, an EV to EBITDA ratio of 23.83, and a PEG ratio of 0.25, showing strong growth potential, while outperforming peers like Halozyme Therapeutics and Elanco Animal Health, and achieving a year-to-date return of 27.36% compared to the S&P 500's 14.40%.

As of 7 November 2025, the valuation grade for Krystal Biotech, Inc. moved from expensive to fair. This suggests that the stock is currently fairly valued. Key valuation ratios include a P/E ratio of 27, an EV to EBITDA ratio of 23.83, and a PEG ratio of 0.25, indicating a strong growth potential relative to its price.<BR><BR>In comparison to its peers, Krystal Biotech's P/E ratio is higher than that of Halozyme Therapeutics, Inc., which has a P/E of 15.92, and significantly above Elanco Animal Health, Inc. at 19.25. Despite this, the company has demonstrated robust performance with a year-to-date return of 27.36%, significantly outpacing the S&P 500's return of 14.40% over the same period, reinforcing the notion that the stock is positioned well in the market.